---
title: "Beijing Luzhu Biotechnology's License Application for Herpes Zoster Vaccine Accepted by Chinese Regulator"
date: "2025-02-10 17:14:04"
summary: "Beijing Luzhu Biotechnology  biologics license application for LZ901 was accepted by China's National Medical Products Administration, a Feb. 9 Hong Kong bourse filing said. LZ901 is a recombinant herpes zoster vaccine candidate aimed at preventing the occurrence of herpes zoster and related complications, according to the drugmaker."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Beijing Luzhu Biotechnology biologics license application for LZ901 was accepted by China's National Medical Products Administration, a Feb. 9 Hong Kong bourse filing said.

LZ901 is a recombinant herpes zoster vaccine candidate aimed at preventing the occurrence of herpes zoster and related complications, according to the drugmaker.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:G2465633:0/)
